Denali Therapeutics Q3 net loss widens to $126.9 mln

Denali Therapeutics

06/11/2025 21:40

Overview

Denali Q3 net loss widens to $126.9 mln from $107.2 mln last year

Operating expenses increased due to R&D and commercial launch preparations

FDA extends tividenofusp alfa review timeline to April 2026 from January

Outlook

Denali expects to launch tividenofusp alfa for Hunter syndrome after FDA review by April 2026

Company plans global Phase 3 study for DNL126 in Sanfilippo syndrome type A

Denali submitted applications to start clinical studies for Alzheimer's and Pompe diseases

Result Drivers

R&D EXPENSES - Increase in R&D expenses driven by operations at new manufacturing facility and personnel-related costs

COMMERCIAL LAUNCH PREPARATIONS - Increase in general and administrative expenses due to preparations for tividenofusp alfa commercial launch

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$126.90 mln
Q3 Basic EPS
-$0.74
Q3 Operating Expenses
$137.43 mln
Q3 Operating Income
-$137.43 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Denali Therapeutics Inc is $30.00, about 50.4% above its November 5 closing price of $14.89

Press Release: ID:nGNX9zKDmR

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)